Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
The Korean Journal of Internal Medicine ; : 899-905, 2015.
Artigo em Inglês | WPRIM | ID: wpr-195228

RESUMO

BACKGROUND/AIMS: In this study, the sensitivity-specificity of galactomannan-enzyme immunoassay (GM-EIA) with a cut-off value of 0.5 for a single, two, or three consecutive positivity in the diagnosis of invasive pulmonary aspergillosis (IPA) in neutropenic patients with hematological malignancy was investigated. METHODS: IPA was classified as "proven," "probable," or "possible" as described in the guidelines prepared by the European Organization for Research and Treatment of Cancer and Mycoses Study Group." Serum samples were collected from the patients twice a week throughout their hospitalization. A total of 1,385 serum samples, with an average of 8.3 samples per episode, were examined. RESULTS: Based on the 165 febrile episodes in 106 patients, 80 (48.5%) were classified as IPA (4 proven, 11 probable, 65 possible) and 85 (51.5%) as non-IPA. The sensitivity/ specificity was 100%/27.1% for a single proven/probable IPA with the cut of value of GM-EIA > or = 0.5, 86.7%/71.8% for two consecutive positive results, and 73.3%/85.9% for three consecutive positive results. CONCLUSIONS: With the galactomannan levels measured twice a week, consecutive sensitivity decreased and specificity increased. Therefore, an increase may be obtained in sensitivity-specificity by more frequent monitoring of GM-EIA starting from the first day of positivity is detected.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antineoplásicos/efeitos adversos , Biomarcadores/sangue , Ensaio de Imunoadsorção Enzimática , Neoplasias Hematológicas/diagnóstico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Hospedeiro Imunocomprometido , Imunossupressores/efeitos adversos , Aspergilose Pulmonar Invasiva/sangue , Mananas/sangue , Infecções Oportunistas/sangue , Valor Preditivo dos Testes , Reprodutibilidade dos Testes , Fatores de Tempo
2.
Clin. biomed. res ; 34(4): 333-341, 2014. ilus, tab
Artigo em Inglês | LILACS | ID: biblio-834486

RESUMO

The phenomenon of transfusion-related immunomodulation (TRIM) has been studied since the observation of a higher kidney allograft survival in patients who had received a higher number of transfusions. Conversely, it has been suggested as one of the possible causes related to the development of infections in patients with multiple blood transfusions and/or after a major surgery, and has been also associated with a decreased function of natural killer cells (NK) and antigen-presenting cells (APCs), reduced cell-mediated immunity, and increased regulatory T cells (Tregs). This review aimed to conceptualize TRIM and discuss some aspects related to its mechanisms and the prevention of immunomodulatory events.


Assuntos
Antígenos HLA/efeitos adversos , Antígenos de Grupos Sanguíneos/efeitos adversos , Antígenos de Grupos Sanguíneos/imunologia , Preservação de Sangue , Imunomodulação , Terapia de Imunossupressão , Procedimentos de Redução de Leucócitos , Tolerância ao Transplante , Transfusão de Sangue/efeitos adversos , Infecções Oportunistas/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA